Molecular biology of polycythemias

Internal Medicine

Volumn 40, Issue 8, 2001, Pages 681-687

  Prchal, Josef T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Erythrocytosis; Erythropoietin; Hematopoiesis; Hypoxia inducible factor (HIF)

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ERYTHROPOIETIN RECEPTOR; SOMATOMEDIN C;

ERYTHROPOIESIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; POLYCYTHEMIA; POLYCYTHEMIA VERA; REVIEW;

ANGIOTENSIN II; ERYTHROPOIESIS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; POLYCYTHEMIA; POLYCYTHEMIA VERA; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RECEPTORS, ERYTHROPOIETIN;

EID: 0035430941     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.40.681     Document Type: Review

References (103)

1. Prchal JT, Sokol L. Benign erythrocytosis and other familial and congenital polycythemias. Eur J Haematol 57: 263-268, 1996.
2. Krantz SB. Erythropoietin. Blood 77: 419-434, 1991.
3. Stopka T, Zivny JH, Stopkova P, Prchal JF, Prchal JT. Human hematopoietic progenitors express erythropoietin. Blood 91: 3766-3772, 1998.
4. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
5. Kvietikova I, Wenger RH, Marti HH, Gassmann M. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 23:4542-4550, 1995.
6. Wiener CM, Booth G, Semenza GL. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 225: 485-488, 1996.
7. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269: 23757-23763, 1994.
8. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76: 839-885, 1996.
9. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 268: 21513-21518, 1993.
10. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578, 1999.
11. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxiamediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998 (published erratum appears in Nature 395: 525, 1998).
12. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998.
13. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000; 35 (2): 71-103, 2001.
14. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237, 1995.
15. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 2000 Apr 25; 97 (9): 4748-4753, 2001.
16. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
17. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000 Aug 18; 275 (33): 25733-25741, 2001.
18. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000 Jul; 2 (7): 423-427, 2001.
19. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J Aug 15; 19: 4298-4309, 2000.
20. Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood 76: 31-35, 1990.
21. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248: 378-381, 1990.
22. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, Lodish HF. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 11: 1980-1987, 1991.
23. Witthuhn BA, Quelle FV, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74: 227-236, 1993.
24. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729-738, 1995.
25. Damen JE, Wakao H, Miyajima A, et al. Tyrosine 343 in the erythropoietin receptor positivery regulates erythropoietin-induced cel proliferation and stat5 activation. EMBO J 14: 5557-5568, 1995.
26. Socolovsky M, Dusanter-Fourt I, Lodish HF. The prolactin receptor and severely truncated erythropoietin receptors support differentiation of erythroid progenitors. J Biol Chem 272: 14009-14012, 1997.
27. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395, 1998.
28. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 14: 2816-2826, 1995.
29. Sasaki A, Yasukoawa H, Shouda T, Kitamura T, Dikic I, Yoshimura I. Cis3/SOCS3 Suppresses erythropoietin signaling by binding to EPOR and JAK2. JBC 38: 29338-29347, 2000.
30. Kralovics R, Sokol L, Broxson EH Jr, Prchal JT. The erythropoietin receptor gene is not linked with polycythemia phenotype in a family with autosomal dominant primary polycythemia. Proc Assoc Am Physicians 109: 580-585, 1997.
31. Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 34: 70-76, 1997.
32. Le Couedic JP, Mitjavila MT, Villeval JL, et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood 87: 1502-1511, 1996.
33. Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulin-like growth factor 1. Blood 78: 2823-2833, 1991.
34. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor 1 in vitro: studies in an improved serum-free medium. Blood 83: 99-112, 1994.
35. Konwalinka G, Geissler D, Peschel C, et al. Human erythropoiesis in vitro and the source of burst-promoting activity in a serum-free system. Exp Hematol 14: 899-903, 1986.
36. Stewart S, Zhu B, Axelrad A. A "serum-free" medium for the production of erythropoietic bursts by murine bone marrow cells. Exp Hematol 12: 309-318, 1984.
37. Kurtz A, Matter R, Eckhardt KU, Zapf J. Erythropoiesis, serum erythropoietin, and serum IGF-I in rats during accelerated growth. Acta Endocrinol (Copenh) 122: 323-328, 1990.
38. Brox AG, Congote LF, Fafard J, Fauser AA. Identification and characterization of an 8-kd peptide stimulating late erythropoiesis. Exp Hematol 17: 769-773, 1989.
39. Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood 89: 1862-1869, 1997.
40. McLellan KC, Hooper SB, Bocking AD, et al. Prolonged hypoxia induced by the reduction of maternal uterine blood flow alters insulin-like growth factor-binding protein-1 (IGFBP-1) and IGFBP-2 gene expression in the ovine fetus. Endocrinology 131: 1619-1628, 1992.
41. Gomez RA, Norwood VF. Developmental consequences of the renin-angiotensin system. Am J Kidney Dis 26: 409-431, 1995.
42. Gomez RA. Angiotensin receptors: relevance in development and disease states. Exp Nephrol 2: 259-268, 1994 (editorial).
43. Ray PE, Aguilera G, Kopp JB, Horikoshi S, Klotman PE. Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney Int 40: 764-771, 1991.
44. Tufro-McReddie A, Gomerz RA. Ontogeny of the renin-angiotensin system. Semin Nephrol 13: 519-530, 1993.
45. Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 9: 1104-1108, 1998.
46. Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of post-transplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 26: 495-500, 1995.
47. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 100: 2310-2314, 1997.
48. Marrero MB, Schieffer B, Paxton WG, et al. Direct stimulation of Jak/ STAT pathway by the angiotensin II AT1 receptor. Nature 375: 247-250, 1995.
49. Prchal JT, Jenkins M. Congenital and Acquired Abnormality of Hemoglobin. 21st edition of Cecil Textbook of Medicine, W.B. Saunders, Philadelphia, 2000.
50. Lichtman MA, Murphy MS, Adamson JW. Detection of mutant hemoglobins with altered affinity for oxygen. A simplified technique. Ann Intern Med 84: 517-520, 1976.
51. Galacteros F, Rosa R, Prehu MO, Najean Y, Calvin MC. Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis. Nouv Rev Fr Hematol 26: 69-74, 1984.
52. Prchal JT, Crist WM, Goldwasser E, Perrine G, Prchal JF. Autosomal dominant polycythemia. Blood 66: 1208-1214, 1985.
53. Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis causes by increased sensitivity to erythropoietin. Blood 78: 3066-3069, 1991.
54. Emanuel PD, Eaves CJ, Broudy VC, et al. Familial and congenital polycythemia in three unrelated families. Blood 79: 3019-3030, 1992.
55. Kralovics R, Prchal JT. Congenital and inherited polycythemia. Curr Opin Pediat 2000 Feb; 12 (1): 29-34, 2001.
56. Damen JE, Krosl J, Morrison D, Pelech S, Krystal G. The hyperres-ponsiveness of cells expressing truncated erythropoietin receptors is contingent on insulin-like growth factor-1 in fetal calf serum. Blood 92: 425-433, 1998.
57. Divoky V, Liu ZY, Ryan T, Prchal JF, Townes TM, Prchal JT. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci USA 98: 986-991, 2001.
58. Sokol L, Prchal JT. Two microsatellite repeat polymorphisms in the EPO gene. Hum Mol Gene 3: 219, 1994.
59. Kralovics R, Sokol L, Prchal JT. Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J Clin Invest 102: 124-129, 1998.
60. Sokol L, Prchal J, Prchal JT. Primary familial and congenital polycythaemia. Lancet 342: 115-116, 1993 (letter).
61. Kralovics R, Sokol L, Broxson EH Jr, Prchal JT. The erythropoietin receptor gene is not linked with the polycythemia phenotype in a family with autosomal dominant primary polycythemia. Proc Assoc Am Physians 109: 580-585, 1997.
62. Kralovics R, Prchal J. Genetic heterogeneity of primary familial and congenital polycythemia. Submitted. 2001.
63. Gazenko L. Pathogenetic features of hereditary erythrocytosis. In Doctoral dissertation (Moscow: Hematological Scientific Center) 1992.
64. Polyakova L. Familial erythrocytosis among inhabitants of the Chuvash ASSR. Probl Gematol 0: 30, 1974.
65. Polyakova L. Familial-Hereditary Erythrocytosis. Thesis (Moscow: Scientific Research Institute of Hematology and Blood Transfusion) 1977.
66. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythemia in Chuvashia. Blood 89: 2148-2154, 1997 (see comments).
67. Ang SO, Buchannan GR, Gordeuk VR, Prchal JT. Putative dysregulation in the HIF-oxygen sensing pathway in congenital Chuvash polycythemia. Blood 94: 412a, 1999.
68. Ang SO, Gordeuk VR, Sergeyeva A, Prchal JT. Chuvash polycythemia: An autosomal recessive disorder of dysregulated oxygen sensing. Blood 96: 5a, 2000 and submitted 2001.
69. Pahl HL. Towards a molecular understanding of polycythemia rubra vera. Eur J Biochem 2000 Jun; 267 (12): 3395-3401, 2001.
70. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 295: 913-916, 1976.
71. Gregg XT, Liu Y, Prchal JT, Gartland GT, Cooper MD, Prchal JF. Clonality in myeloproliferative disorders. Blood 88 (suppl 1): 1905a (Abstract), 1996 (Abstract).
72. Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Eng J Med 290: 1382, 1974.
73. Weinberg RS. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 34: 64-69, 1997.
74. Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma 22 (Suppl 1): 95-103, 1996.
75. Casadevall N, Vainchenker W, Lacombe C, et al. Erythroid progenitors in polycy themia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures. Blood 59: 447-451, 1982.
76. Prchal JF, Prchal JT. Molecular Basis for Polycythemia. in: Current Opinion in Hematology. 6: Lippincott Williams & Wilkins, 1999: 100-109. Inc.
77. Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 83: 744-748, 1994.
78. Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia. Blood 84: 1982-1991, 1994.
79. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 90: 2057-2061, 1997.
80. Dai CH, Krantz SB, Dessypris EN, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera II, Hypersensitivity of bone marrow erythroid, glanulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 80: 891-899, 1992.
81. Dai CH, Krantz SR, Means RT Jr, Horn ST, Gilbert HS. Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3. J Clin Invest 87: 391-396, 1991.
82. Kralovics R, Prchal JT. Hematopoietic progenitors and signal transduction in polycythemia vera and primary thrombocythemia. in Bailliere's Clinical Haematology. International Practice and Research. Green & Pearson, Eds. Myeloproliferative Diseases. Bailliere Tindall, London, 1998.
83. Prchal J, Prchal J, Kralovics R, Eskinazi D, Axelrad A. Sensitivities of erythroid progenitor cells to erythropoietin (EPO) and insulin-like growth factor-1 (IGF-1) in patients with primary familial and congenital polycythemia (PFCP): Studies in strictly serum-free conditions. Exp Hematol 26: 239, 1998.
84. Hess G, Rose P, Gamm H, Papadileris S, Huber C, Seliger B. Molecular analysis of the erythropoietin receptor system in patients with polycythemia vera. Br J Haematol 88: 794-802, 1994.
85. Streuli M. Protein tyrosinephosphatases in signaling. Curr Opin Cell Biol 8: 182-188, 1996.
86. Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73: 1445-1454, 1993.
87. Andersson P, LeBlanc K, Eriksson BA, Samuelsson J. No evidence for an altered mRNA expression or protein level or haematopoietic cell phosphate in CD34+ bone marrow progenitor cells or mature peripheral blood cells in polycythemia vera. Eur J Haematol 59: 310-317, 1997.
88. Asimakopoulos FA, Hinshelwood S, Gilbert G, et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene 14: 1215-1222, 1997.
89. Wickrema A, Chen F, Namin F, et al. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol 27: 1124-1132, 1999.
90. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 338: 572-580, 1998 (see comments).
91. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338: 564-571, 1998 (see comments).
92. Ushikubi F, Ishibashi T, Narumiya S, Okuma M. Analysis of the defective signal transduction mechanism through the platelet thromboxane A2 receptor in a patient with polycythemia vera. Thromb and Haemost 67: 144-146, 1992.
93. Le Blanc K, Berg A, Palmblad J, Samuelsson J. Stimulus-specific defect in platelet aggregation in polycythemia vera. Eur J Haematol 53: 145-149, 1994.
94. Samuelsson J, Forslid J, Hed J, Palmblad J. Studies of neutrophil and monocyte oxidative responses in polycythemia vera and related myeloproliferative disorders. Br J Haematol 87: 464-470, 1994.
95. Katoh O, Kimura A, Itoh T, Kuramoto A. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 35: 145-150, 1990.
96. Sui X, Krantz SB, Zhao Z. Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood 90: 651-657, 1997.
97. Dai CH, Krantz SB, Sawyer ST. Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. Blood 89: 3574-3581, 1997.
98. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduce expression of platelet c-mpl receptor in essential thrombocythemia. Blood 90: 4031-4038, 1997.
99. Nakamura Y, Nakauchi H. A truncated erythropoietin receptor and cell death: a reanalysis. Science 264: 588-589, 1994 (letter).
100. Chiba S, Takahashi T, Takeshita K, et al. Selective expression of mRNA coding for the truncated form of erythropoietin receptor in hematopoietic cells and its decrease in patients with polycythemia vera. Blood 90: 97-104, 1997.
101. Temerinac S, Klippel S, Strunck E et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95 (8): 2569-2576, 2001.
102. Kralovics R, Castillos FA, Prchal JT. Familial polycythemia vera: Mode of inheritance, clonality, and genetic analysis of candidate genes and chromosomal regions. Blood 94: 113a, 1999.
103. Kralovics R, Prchal JT. Involvement of chromosome 9 and 11 in familial and sporadic polycythemia vera. Exp Hematol 28: 65a, 2000.